https://doi.org/10.18549/PharmPract.2017.01.877app

Online supplementary materials

Table 1. Characteristics of the included clinical trails

Author/year	Mizukami [29]	Navari 2011[21]	Tan 2009 [24]	Wang2015[26]	Mukhopadhyay2017 [30]	Navari *2016 [20]
Study design	Randomized, single-blind, placebo controlled trial	Randomized control trial; unblended	Randomized control trial; unblinded	Randomized controlled trial	Randomized, double blinded controlled trial	Double blinded randomized trial
Total No. of patients	44	241	247	84	100	120
No. of patients OL /Control	22/22	121/120	121/108	42/42	50/50	59/59
Type of cancer	Breast , Bladder,, Lymphoma, Pharynx, Leukemia, Other	Bladder , Breast , Lung (non-small cell) , Malignant lymphoma	Lung , Stomach , Breast , Ovarian Lymphom, Oesophageal, Colorectal Oropharyngeal, Teratoma	Non-small cell lung cancer (NSCLC)	N/A	Head and neck or esophageal cancer
Chemotherapy used with degree of emetogenicity	HEC CDDP EC 3 AC 2 MEC Nedaplatin Carboplatin Others	HEC Cisplatin Doxorubicin and cyclophosphamide	HEC cisplatin dacarbazine MEC oxaliplatin epirubicin doxorubicin carboplatin	HEC Cisplatin- gemcitabine regimen	HEC cisplatin, carboplatin, and oxaliplatin	HEC plus radiation therapy
Intervention	C: corticosteroid + 5 HT3 receptor antagonist + NK-1 receptor antagonist O: C regimen + O 5 mg/d days 0–5	C: aprepitant, palonosetron ,dexamethasone, (APD) regimen O: O 10 mg PO 1-4 days, palonosetron, and dexamethasone (OPD) regimen	C:corticosteroid (dexamethasone) + 5-HT3 receptor Antagonist(azasetron) O: C regimen + O 10 mg/d days 1–5	C:Ondansetron 8 mg 30 min before chemo O: O 10 mg/day 1–8 Ondansetron 8 mg 30 min before chemo	C: Palonosetron d 1 Dexamethasone d 1 O: C regimen + O10 mg/day 1–5	C: fosaprepitant, Dexamethasone Palonosetron (FPD) O: C regimen +O 10 mg
Age range	22-78	39—81	18-74	39-76	55.04 ± 1.50 (median)	52-76
Ethnicity	Japanese	Americans	Chinese	Chinese	Indian	Americans

https://doi.org/10.18549/PharmPract.2017.01.877app

Table 1. Characteristics of the included clinical trails (cont.)

Author and /year	Navari 2016[32]	Shumway 2009 [23]	Navari 2015 [22]	Mao 2011[28]	Wang 2012 [25]	Lu et al. 2013[27]	Babu 2016 [31]
Study design	Randomized, double-blind, placebo controlled trial	Randomized, single-blind, placebo-controlled trial	Randomized, single-blind, controlled trial	Randomized controlled trial	Randomized controlled trial	Randomized controlled trial	Randomized control trial
Total No. of patients	380	18	101	92	120	60	100
No. of patients OL /Control	192/188	8/9	51/50	46/46	60/60	30/30	50/50
Type of cancer	Breast, Lung Other	N/A	head and neck and esophageal cancer	N/A	N/A	Solid malignant tumors	Breast, lymphoma, head and neck. Osteosarcoma, stomach
Chemotherapy used with degree of emetogenesity	HEC Cisplatin-containing regimen Anthracycline and cyclophosphamide	HEC cisplatin AC ABVD	HEC cisplatin based and radiation therapy	MEC or HEC	HEC	MEC or HEC	HEC
Intervention	C: dexamethasone, NK1-receptor antagonist , and a 5-HT3–receptor antagonist O: C regimen + 10 mg of olanzapine day 1-4	C: Placebo d-2, d-1,d d 4, Aprepitant 125 mg PO d 1, 80 mg PO d 2–3, Dexamethasone 12 mg IV d 1, 4 mg PO BID d 2–4, Palonosetron 0.25mg IV d-1 O: Olanzapine 5 mg PO d −2, d −1,d 10 mg PO d 1–4 Dexamethasone 12 mg IV d 1, 4 mg PO BID d 2–4 Palonosetron 0.25 mg IV d 1	C: Fosaprepitant 150 mg IV d 1, Palonosetron 0.25 mg IV d 1, Dexamethasone 12 mg IV d 14 mg BID d 2–3 O: Olanzapine 10 mg/day d 1–4, Palonosetron 0.25 mg IV d1. Dexamethasone 20 mg IV pre-chemo d 1	C: Corticosteroid 5-HT3 receptor antagonist O: Olanzapine 10 mg/day days unspecified Corticosteroid 5-HT3 receptor antagonist	C: 5-HT3 receptor antagonist O: C regimen + Olanzapine 10 mg/d days 1–8	C: diphenhydramine, corticosteroid , 5-HT3 receptor antagonist O: C regimen + Olanzapine 5 mg/d days 1	C: aprepitant 125mg d 1, 80 mg d 2-3 Palonosetron 0.25 mg iv d 1, dexamethasone 12 mg iv d 1 Dexamethasone 4 mg twice bid p.o d 2-4 O: C plus O 10 mg p.o. day 1 O 5 mg bid p.0 d 2-4 P
Age Median(range)	28.0–89.0	24-71	52-76	---	--	---	Average 43.3/average 44.7
Ethnicity	Americans	Americans	Americans	Chinese	Chinese	Chinese	Indian

Abbreviations: ABVD chemotherapy drug combination that includes adriamycin, bleomycin, vinblastine, and dacarbazine; AC doxorubicin and cyclophosphamide; BID two times a day; CR complete response; d day; HEC highly emetogenic chemotherapy; MEC moderately emetogenic chemotherapy; metoclo metoclopramide; N/A not available; ondanondansetron; palo palonosetron; PO oralintake.